


PATENT
ST98014AIN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): RHOLAM ET AL. EXAMINER : UNASSIGNED
SERIAL NO. : 09/701,945 ART UNIT : UNASSIGNED
FILED : December 5, 2000
FOR : POLYPEPTIDES WHICH POSSESS AN ACTIVITY OF THE β -
SECRETASE TYPE

CERTIFICATE OF MAILING UNDER 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service via First Class mail in an envelope addressed to the COMMISSIONER FOR PATENTS, WASHINGTON, DC 20231

On 08/09/02


(Signature and Date)RESPONSE TO NOTIFICATION OF MISSING REQUIREMENTS

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

Dear Sir:

In a Notification of Missing requirements under 35 U.S.C. § 371 issued on May 30, 2002, a copy of which is attached hereto, the United States Patent and Trademark Office (USPTO) asserted that the current oath or declaration filed in the instant Application does not comply with 37 CFR §1.497(a) in that it is not executed in accordance with either 37 CFR § 1.66 or 37 CFR § 1.68.

In response, Applicants respectfully submit that an executed declaration which identified the application by the international application number and international filing

date was indeed filed with the United States Patent and Trademark Office in this matter on May 11, 2001. Furthermore, on January 7, 2002, Applicants submitted an executed supplemental declaration in order to claim priority from French application FR 98 07068.

In support of Applicant's position, submitted herewith are copies of the following:

- (a) the executed declaration filed May 11, 2001 with the United States Patent and Trademark Office;
- (b) the transmittal letter of May 11, 2001 indicated the submission of the executed declaration;
- (c) the return postcard confirming the USPTO's receipt of the executed declaration filed May 11, 2001;
- (d) Submission of the supplemental declaration and power of attorney filed January 7, 2002; and
- (e) The executed supplemental declaration and power of attorney filed January 7, 2002.


Fees

Since it is Applicants' position that the Notice mailed on May 30, 2002 was erroneously issued in light of Applicants' previous submission of an executed Declaration, no fees are due for this response. However, should this be erroneous, authorization is hereby given to charge Deposit Account No. 18-1982 for any underpayment, or credit any overages.

CONCLUSION

In light of the copies of documents submitted herewith, Applicants have indeed completed the requirements for the above-identified Application under 35 U.S.C. § 371, and request that the instant Application be granted a 35 U.S.C. § 102(e) date of May 11, 2001. Early and favorable action on the pending Claims is respectfully solicited.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'William C. Coppola', written over a horizontal line.

William C. Coppola
Registration No. 41,686

AVENTIS PHRAMACEUTICALS PRODUCTS INC.
Route 202-206; Mail Stop: EMC-G1
P.O. Box 6800
Bridgewater, NJ 08807
August 7, 2002

APPLICANTS	PCT/FR99/01326	SERIAL NO.	99/701,945	DATE	5-11-01
DOCKET NO.	ST 98084A	ATTY	W.C.C.		
APPLICANT(S)	MOHAMED RHOLAN et al.				
TITLE OF INVENTION:	Polypeptides Which Possess an Activity etc.				

The Patent Office acknowledges and has stamped hereon the date of receipt of the items checked below:

<input type="checkbox"/> Affidavit/Declaration, 37 CFR _____	<input type="checkbox"/> Maintenance fee transmittal
<input type="checkbox"/> Amendment, 37 CFR _____	<input type="checkbox"/> Patent Application
<input type="checkbox"/> Appeal notice/Appeal Brief	_____ # of pages _____ # of pages of claims
<input type="checkbox"/> Assignment & Cover Sheet	_____ # of sheets of drawings
<input type="checkbox"/> Cert. of correction request	_____ Declaration/Oath: _____ signed _____ unsigned
<input checked="" type="checkbox"/> Cert. of Exp. Mailing, Date: <u>5-11-01</u>	_____ Transmittal letter
No. <u>EL 685154885 US</u>	<input type="checkbox"/> PCT Application, transmittal, request & fee sheet
<input checked="" type="checkbox"/> Charge deposit account, in duplicate	<input type="checkbox"/> Petition under 37 CFR _____
<input type="checkbox"/> Check \$ _____ for _____	<input checked="" type="checkbox"/> Power of attorney <u>Signed</u>
<input type="checkbox"/> Demand for PCT examination	<input type="checkbox"/> Priority claim
<input type="checkbox"/> Extension of time petition	<input type="checkbox"/> Reply, 37 CFR _____
<input type="checkbox"/> IDS (information disclosure statement)	<input checked="" type="checkbox"/> Other <u>Second Submission -</u>
PTO Form 1449: # of pages enc. _____	<u>Transmittal Letter to US</u>
# of reference enc. _____	<u>Designated/Elected Office</u>
<input type="checkbox"/> Issue fee transmittal & advance order	PTO Date Stamp and Return <u>35 USC 371</u>

1097 RCD PCTO 11 MAY 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
Rholam et al.

Examiner:

Art Unit:

Serial No.: 09/701,945

Filed: December 5, 2000

Title: POLYPEPTIDES WHICH POSSESS
AN ACTIVITY OF THE β -
SECRETASE TYPE

I hereby certify that this correspondence is being
deposited with the United States Postal Service as First
Class Mail in an envelope addressed to Commissioner
for Patents, Washington, D.C. 20231, on

11/7/02
Date of Deposit

Signature

Jolly Kapadia

SUBMISSION OF SUPPLEMENTAL DECLARATION AND POWER OF ATTORNEY
FILED UNDER 37 C.F.R. 1.67

Commissioner for Patents
Washington, D.C. 20231

Sir:

On May 11, 2001, Applicants submitted a Declaration and Power of Attorney in the above-mentioned patent application. However, the French priority information was not claimed on that document. Therefore, Applicants submit herewith a Supplemental Declaration for the present application and claim priority from French Application FR 98 07068 filed 5 June 1998.

Please charge the \$130.00 fee involved to Deposit Account No. 18-1982. The Commissioner is hereby authorized to charge any additional fees which may be required by this paper, or credit any overpayment to Account No. 18-1982. Two duplicate copies of this sheet are enclosed.

Respectfully submitted,



William C. Coppola, Reg. No. 41,686
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-4854
Telefax (908) 231-2626

Docket No. ST98014A US PCT



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents, Box PCT
United States Patent and Trademark Office
Washington, D.C. 20231
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
09/701,945	Mohamed Rholam	ST98014A

5487

AVENTIS PHARMACEUTICALS, INC.
PATENTS DEPARTMENT
ROUTE 202-206, P.O. BOX 6800
BRIDGEWATER, NJ 08807-0800



INTERNATIONAL APPLICATION NO.	
PCT/FR99/01326	
LA. FILING DATE	PRIORITY DATE
06/04/1999	06/05/1998

CONFIRMATION NO. 9850

371 FORMALITIES LETTER



OC000000008200954

Date Mailed: 05/30/2002

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fees
- Priority Document
- Biochemical Sequence Diskette
- Biochemical Sequence Listing
- Copy of IPE Report
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Oath or Declaration
- Preliminary Amendments

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date. The current oath or declaration does not comply with 37 CFR 1.497(a) and (b) in that it:
 - is not executed in accordance with either 37 CFR 1.66 or 37 CFR 1.68.

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTH FROM THE DATE OF THIS NOTICE OR BY 22 or 32 MONTHS (where 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

DEBORAH D WILLIAMS

Telephone: (703) 305-3744

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
09/701,945	PCT/FR99/01326	ST98014A

FORM PCT/DO/EO/905 (371 Formalities Notice)